CLANZA CR- aceclofenac tablet, film coated

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

Aceclofenac (UNII: RPK779R03H) (Aceclofenac - UNII:RPK779R03H)

Inapatikana kutoka:

United Douglas Pharm., Inc.

INN (Jina la Kimataifa):

Aceclofenac

Tungo:

Aceclofenac 200 mg

Njia ya uendeshaji:

ORAL

Dawa ya aina:

PRESCRIPTION DRUG

Matibabu dalili:

INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. CONTRAINDICATIONS Patients with allergy to these drugs or other analogues (diclofenac). Patients with asthma. Like NSAIDS, acetylsalicylic acid and other drugs which inhibit prostagladin-synthesis may precipitate attacks of asthma, acute rhinitis or urticaria. Patients with active peptic ulcer. USE IN CHILDREN The dosage and indication is not established yet for children with less than 6 years old.

Bidhaa muhtasari:

PACKAGE 10 Blister Packs with 10 Tablets in each Blister Pack

Idhini hali ya:

Export only

Tabia za bidhaa

CLANZA CR- ACECLOFENAC TABLET, FILM COATED
UNITED DOUGLAS PHARM., INC.
----------
DESCRIPTION
White, oblong, film-coated tablet, engraved with "UT" on one side and
"CL CR" on the other side.
INDICATIONS
CLANZA CR is indicated for Rheumatoid arthritis, ankylosing
spondylitis, osteoarthritis and
periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by
nonaticular rheutism.
Dosage and Administration
Adults: The recommended dose is 200 mg daily, taken as one dose (every
24 hours). However, the
dose and dose frequency of CLANZA CR can be modified under the
supervison of physician or
pharmacist.
CONTRAINDICATIONS
Patients with allergy to these drugs or other analogues (diclofenac).
Patients with asthma. Like
NSAIDS, acetylsalicylic acid and other drugs which inhibit
prostagladin-synthesis may precipitate
attacks of asthma, acute rhinitis or urticaria. Patients with active
peptic ulcer.
CAUTIONS
Patients with symptoms indicative of gastro-intestinal disorders, with
a history of gastroulceration.
Patients with severe hepatic impairment or cardiac or renal
impairment. Patients under the medication of
diuretics. Patients in recovery after surgical treatment.
ADVERSE REACTIONS
The majority of side effects observed have been reversible and of a
minor nature and include gastro-
intestinal disorders (dyspepsia, abdominal pain, nausea), rash, ruber,
urticaria, symptoms of enuresis,
headache, dizziness, and drowsiness. To report suspected adverse
reactions, call 1-800-FDA-1088.
GENERAL PRECAUTIONS
Patients suffering from dizziness, vertigo, or other central nervous
system disorders while taking
NSAIDS should refrain from driving or handling dangerous machinery.
DRUG INTERACTIONS
There has been no drug interactions reported, but close monitoring of
patients on combination with
lithium and digoxin, oral antidiabetic agents, anticoagulants,
diuretics, and other analgesics.
USE IN PREGNANCY AND NURSING MOTHERS
Since there is no information on the safe use of CLANZA CR during
pregnancy and lactation, the use of
CLANZA C